Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Janus Henderson Group plc Reports First Quarter 2019 Diluted EPS of US$0.48, or US$0.56 on an Adjusted Basis

Published

on

Reading Time: 13 minutes

  • Strong investment performance, with 69% and 74% of assets under
    management (“AUM”) outperforming relevant benchmarks on a 3 and 5 year
    basis, respectively, as at 31 March 2019
  • First quarter net income of US$94.1 million and adjusted net income of
    US$110.0 million
  • AUM of US$357.3 billion, up 9% compared to the prior quarter,
    reflecting positive markets partially offset by net outflows of US$7.4
    billion
  • Completed US$31 million of share buybacks during March; US$169 million
    remains authorised for buybacks in 2019
  • Board declared quarterly dividend of US$0.36 per share

LONDON–(BUSINESS WIRE)–Janus Henderson Group plc (NYSE/ASX: JHG; ‘JHG’, ‘the Group’) published
its first quarter 2019 results for the period ended 31 March 2019.

First quarter 2019 net income attributable to JHG was US$94.1 million
compared to US$106.8 million in the fourth quarter 2018 and US$165.2
million in the first quarter 2018. Adjusted net income attributable to
JHG, adjusted for one-time, acquisition and transaction related costs,
of US$110.0 million declined 6% compared to US$117.5 million in the
fourth quarter 2018 and declined 23% compared to US$143.6 million in the
first quarter 2018.

First quarter 2019 diluted earnings per share was US$0.48 compared to
US$0.54 in the fourth quarter 2018 and US$0.82 in the first quarter
2018. Adjusted diluted earnings per share of US$0.56 declined 5%
compared to US$0.59 in the fourth quarter 2018 and declined 21% versus
US$0.71 in the first quarter 2018.

Dick Weil, Chief Executive Officer of Janus Henderson Group plc,
stated:

“Overall investment performance for the quarter was strong, but we
continue to face pockets of underperformance which are driving
substantial net outflows. That said, we are seeing encouraging results
in several areas of our business, including momentum in the US retail
channel, primarily with our US Equity strategies, ongoing growth in our
Multi-Asset capability, and an improving environment in Continental
Europe.

“We finished the quarter with a 9% increase in assets under management
as strong investment performance and rebounding markets offset outflows.

“We continue to be financially disciplined, remaining focused on
investing in sustainable growth and upholding our commitment to return
cash flow to shareholders, with over US$100 million returned through
dividends and our share buyback programme in the first quarter.”

SUMMARY OF FINANCIAL RESULTS (unaudited) (in US$ millions,
except per share data or as noted)

The Group presents its financial results in US$ and in accordance with
accounting principles generally accepted in the United States of America
(‘US GAAP’ or ‘GAAP’). However, in the opinion of Management, the
profitability of the Group and its ongoing operations is best evaluated
using additional non-GAAP financial measures on an adjusted basis. See
adjusted statements of income reconciliation for additional information.

    Three months ended
31 Mar     31 Dec     31 Mar
  2019 2018 2018

GAAP basis:

Revenue 519.3 545.1 587.7
Operating expenses 394.8 395.1 411.5
Operating income 124.5 150.0 176.2
Operating margin 24.0% 27.5% 30.0%
Net income attributable to JHG 94.1 106.8 165.2
Diluted earnings per share 0.48 0.54 0.82
 
 
Three months ended
31 Mar 31 Dec 31 Mar
  2019 2018 2018

Adjusted basis:

Revenue 417.4 442.7 470.4
Operating expenses 274.0 277.4 281.6
Operating income 143.4 165.3 188.8
Operating margin 34.4% 37.3% 40.1%
Net income attributable to JHG 110.0 117.5 143.6
Diluted earnings per share 0.56 0.59 0.71
 

First quarter 2019 adjusted revenue of US$417.4 million decreased from
the fourth quarter 2018 result of US$442.7 million due to a slight
decline in management fee margin, given outflows in higher fee equity
products, and lower performance fees from segregated mandates. First
quarter 2019 adjusted operating income of US$143.4 million decreased
from US$165.3 million in the fourth quarter 2018, with lower adjusted
revenue slightly offset by lower operating expenses.

DIVIDEND AND SHARE BUYBACK

On 1 May 2019, the Board declared a first quarter dividend in respect of
the three months ended 31 March 2019 of US$0.36 per share. Shareholders
on the register on the record date of 13 May 2019 will be paid the
dividend on 29 May 2019. Janus Henderson does not offer a dividend
reinvestment plan.

As part of the US$200 million on-market buyback programme approved by
the Board in February, JHG purchased approximately 1.3 million of its
ordinary shares on the NYSE and its CHESS Depositary Interests (CDIs) on
the ASX in March, for a total outlay of US$31 million.

During the first quarter, the firm also purchased shares on market for
the annual share grants associated with 2018 variable compensation,
which is not connected with the buyback programme. As a firm policy,
Janus Henderson does not issue new shares to employees as part of its
annual compensation practices.

Net tangible assets per share

US$     31 Mar 2019     31 Dec 2018
Net tangible assets per ordinary share   1.31   1.32
 

Net tangible assets are defined by the ASX as being total assets less
intangible assets less total liabilities ranking ahead of, or equally
with, claims of ordinary shares.

AUM AND FLOWS (in US$ billions)

FX reflects movement in AUM resulting from changes in foreign currency
rates as non-USD denominated AUM is translated into USD. Redemptions
include impact of client switches. The reclassification in the fourth
quarter 2018 reflects an operational reclassification of an existing
client’s funds.

     

Total Group comparative AUM and flows

Three months ended
31 Mar       31 Dec       31 Mar
2019 2018 2018
Opening AUM 328.5 378.1 370.8
Sales 15.6 16.6 19.7
Redemptions (23.0 ) (25.0 ) (22.4 )
Net sales / (redemptions) (7.4 ) (8.4 ) (2.7 )
Market / FX 36.2   (41.2 ) 3.8  
Closing AUM 357.3 328.5 371.9
 
                                 

Quarterly AUM and flows by capability

Equities Fixed

Income

Quantitative

Equities

Multi-Asset Alternatives Total
AUM 31 Mar 2018 190.7 80.0 50.4 31.8 19.0 371.9
Sales 8.5 5.0 0.4 1.8 1.4 17.1
Redemptions (9.6 ) (5.6 ) (1.2 ) (1.3 ) (2.1 ) (19.8 )
Net sales / (redemptions) (1.1 ) (0.6 ) (0.8 ) 0.5 (0.7 ) (2.7 )
Market / FX 3.7   (2.9 ) 0.5   0.3   (0.7 ) 0.9  
AUM 30 Jun 2018 193.3 76.5 50.1 32.6 17.6 370.1
Sales 6.8 6.0 1.3 2.2 1.4 17.7
Redemptions (9.9 ) (7.6 ) (1.3 ) (1.3 ) (1.9 ) (22.0 )
Net sales / (redemptions) (3.1 ) (1.6 ) (0.0 ) 0.9 (0.5 ) (4.3 )
Market / FX 9.0   (0.4 ) 2.8   1.1   (0.2 ) 12.3  
AUM 30 Sep 2018 199.2 74.5 52.9 34.6 16.9 378.1
Sales 8.6 4.7 0.3 2.3 0.7 16.6
Redemptions (12.7 ) (6.0 ) (1.4 ) (2.0 ) (2.9 ) (25.0 )
Net sales / (redemptions) (4.1 ) (1.3 ) (1.1 ) 0.3 (2.2 ) (8.4 )
Market / FX (29.2 ) (1.3 ) (7.5 ) (2.5 ) (0.7 ) (41.2 )
Reclassification 1.7   0.5     (2.2 )    
AUM 31 Dec 2018 167.6 72.4 44.3 30.2 14.0 328.5
Sales 6.9 4.9 0.7 2.2 0.9 15.6
Redemptions (9.8 ) (7.7 ) (1.7 ) (1.5 ) (2.3 ) (23.0 )
Net sales / (redemptions) (2.9 ) (2.8 ) (1.0 ) 0.7 (1.4 ) (7.4 )
Market / FX 24.1   2.9   6.3   2.5   0.4   36.2  
AUM 31 Mar 2019 188.8 72.5 49.6 33.4 13.0 357.3
 
     

Average AUM

Three months ended
31 Mar

2019

      31 Dec

2018

      31 Mar

2018

Equities 182.8 179.5 194.6
Fixed Income 73.3 73.0 79.7
Quantitative Equities 48.3 47.6 51.4
Multi-Asset 32.1 32.2 32.1
Alternatives 13.5 15.5 19.6
Total 350.0 347.8 377.4
 

INVESTMENT PERFORMANCE

% of AUM outperforming benchmark (at 31 Mar 2019)

Capability       1 year       3 years       5 years
Equities 64% 69% 77%
Fixed Income 58% 92% 89%
Quantitative Equities 15% 14% 12%
Multi-Asset 88% 91% 91%
Alternatives 89% 98% 100%
Total 60% 69% 74%

Note: Outperformance is measured based on composite performance gross of
fees vs primary benchmark, except where a strategy has no benchmark
index or corresponding composite in which case the most relevant metric
is used: (1) composite gross of fees vs zero for absolute return
strategies, (2) fund net of fees vs primary index or (3) fund net of
fees vs Morningstar peer group average or median. Non-discretionary and
separately managed account assets are included with a corresponding
composite where applicable.

Cash management vehicles, ETFs, Managed CDOs, Private Equity funds and
custom non-discretionary accounts with no corresponding composite are
excluded from the analysis. Excluded assets represent 4% of AUM as at 31
Mar 2019. Capabilities defined by Janus Henderson.

% of mutual fund AUM in top 2 Morningstar quartiles (at 31 Mar 2019)

Capability       1 year       3 years       5 years
Equities 78% 72% 86%
Fixed Income 68% 42% 48%
Quantitative Equities 63% 3% 97%
Multi-Asset 84% 86% 88%
Alternatives 93% 33% 94%
Total 78% 67% 81%

Note: Includes Janus Investment Fund, Janus Aspen Series and Clayton
Street Trust (US Trusts), Janus Henderson Capital Funds (Dublin based),
Dublin and UK OEIC and Investment Trusts, Luxembourg SICAVs and
Australian Managed Investment Schemes. The top two Morningstar quartiles
represent funds in the top half of their category based on total return.
On an asset-weighted basis, 80% of total mutual fund AUM was in the top
2 Morningstar quartiles for the 10-year period ended 31 Mar 2019. For
the 1-, 3-, 5- and 10-year periods ending 31 Mar 2019, 62%, 50%, 62% and
62% of the 205, 195, 181 and 141 total mutual funds, respectively, were
in the top 2 Morningstar quartiles.

Analysis based on ‘primary’ share class (Class I Shares, Institutional
Shares or share class with longest history for US Trusts; Class A Shares
or share class with longest history for Dublin based; primary share
class as defined by Morningstar for other funds). Performance may vary
by share class. Rankings may be based, in part, on the performance of a
predecessor fund or share class and are calculated by Morningstar using
a methodology that differs from that used by Janus Henderson.
Methodology differences may have a material effect on the return and
therefore the ranking. When an expense waiver is in effect, it may have
a material effect on the total return, and therefore the ranking for the
period.

ETFs and funds not ranked by Morningstar are excluded from the analysis.
Capabilities defined by JHG. © 2019 Morningstar, Inc. All Rights
Reserved.

SECOND QUARTER 2019 RESULTS

Janus Henderson intends to publish its second quarter 2019 results on 31
July 2019.

FIRST QUARTER 2019 RESULTS BRIEFING INFORMATION

Chief Executive Officer Dick Weil and Chief Financial Officer Roger
Thompson will present these results on 2 May 2019 on a conference call
and webcast to be held at 8am EDT, 1pm BST, 10pm AEST.

Those wishing to participate should call:

United Kingdom       0800 358 6377 (toll free)
US & Canada 800 239 9838 (toll free)
Australia 1 800 573 793 (toll free)
All other countries: +1 323 794 2551 (this is not a toll free number)
Conference ID: 6246882
 

Access to the webcast and accompanying slides will be available via the
investor relations section of Janus Henderson’s website (www.janushenderson.com/IR).

About Janus Henderson

Janus Henderson Group (JHG) is a leading global active asset manager
dedicated to helping investors achieve long-term financial goals through
a broad range of investment solutions, including equities, fixed income,
quantitative equities, multi-asset and alternative asset class
strategies.

Janus Henderson has approximately US$357 billion in assets under
management (at 31 March 2019), more than 2,000 employees, and offices in
28 cities worldwide. Headquartered in London, the company is listed on
the New York Stock Exchange (NYSE) and the Australian Securities
Exchange (ASX).

FINANCIAL DISCLOSURES

Period ending 31 March 2018 reflects the reclassification of certain
revenue amounts from ‘Other revenue’ to ‘Shareowner servicing fees’.

     

Condensed consolidated statements of comprehensive income
(unaudited)

 
Three months ended
31 Mar       31 Dec       31 Mar
(in US$ millions, except per share data or as noted) 2019 2018 2018
Revenue:
Management fees 441.9 452.3 502.9
Performance fees (5.6 ) 3.5 (3.9 )
Shareowner servicing fees 35.9 37.0 38.4
Other revenue 47.1   52.3   50.3  
Total revenue 519.3   545.1   587.7  
 
Operating expenses:
Employee compensation and benefits 145.0 155.8 146.7
Long-term incentive plans 48.4 32.3 40.0
Distribution expenses 101.9 102.4 117.3
Investment administration 11.8 11.6 11.4
Marketing 7.5 12.8 8.5
General, administrative and occupancy 65.2 62.4 72.2
Depreciation and amortisation 15.0   17.8   15.4  
Total operating expenses 394.8   395.1   411.5  
 
Operating income 124.5 150.0 176.2
 
Interest expense (4.1 ) (4.0 ) (3.8 )
Investment gains (losses), net 13.3 (15.3 ) (0.7 )
Other non-operating income (expenses), net (3.9 ) 13.5   38.9  
Income before taxes 129.8 144.2 210.6
Income tax provision (29.9 ) (43.4 ) (47.4 )
Net income 99.9 100.8 163.2
Net loss (income) attributable to noncontrolling interests (5.8 ) 6.0   2.0  
Net income attributable to JHG 94.1 106.8 165.2
Less: allocation of earnings to participating stock-based awards (2.4 ) (2.8 ) (4.2 )
Net income attributable to JHG common shareholders 91.7   104.0   161.0  
 
Basic weighted-average shares outstanding (in millions) 191.8 193.3 195.9
Diluted weighted-average shares outstanding (in millions) 192.5 194.1 196.9
 
Diluted earnings per share (in US$) 0.48 0.54 0.82
 

Adjusted statements of income (unaudited)

The following are reconciliations of US GAAP basis revenues, operating
income, net income attributable to JHG and diluted earnings per share to
adjusted revenues, adjusted operating income, adjusted net income
attributable to JHG and adjusted diluted earnings per share.

      Three months ended
31 Mar       31 Dec       31 Mar
(in US$ millions, except per share data or as noted) 2019 2018 2018
Reconciliation of revenue to adjusted revenue
Revenue 519.3 545.1 587.7
Distribution expenses1 (101.9 ) (102.4 ) (117.3 )
Adjusted revenue 417.4   442.7   470.4  
 
Reconciliation of operating income to adjusted operating income
Operating income 124.5 150.0 176.2
Employee compensation and benefits2,4 4.3 4.4 2.9
Long-term incentive plans2 (0.2 ) (0.2 ) 0.1
Marketing2 0.1 0.1
General, administration and occupancy2,4 7.4 1.9 2.1
Depreciation and amortisation2,3 7.4   9.1   7.4  
Adjusted operating income 143.4   165.3   188.8  
 
Operating margin 24.0 % 27.5 % 30.0 %
Adjusted operating margin 34.4 % 37.3 % 40.1 %
 
Reconciliation of net income attributable to JHG to adjusted net
income attributable to JHG
Net income attributable to JHG 94.1 106.8 165.2
Employee compensation and benefits2,4 4.3 4.4 2.9
Long-term incentive plans2 (0.2 ) (0.2 ) 0.1
Marketing2 0.1 0.1
General, administration and occupancy2,4 7.4 1.9 2.1
Depreciation and amortisation2,3 7.4 9.1 7.4
Interest expense4 0.9 0.9 0.7
Other non-operating income (expenses), net4 0.4 0.3 (44.8 )
Income tax provision5 (4.3 ) (5.8 ) 9.9  
Adjusted net income attributable to JHG 110.0 117.5 143.6
Less: allocation of earnings to participating stock-based awards (2.8 ) (3.2 ) (3.6 )
Adjusted net income attributable to JHG common shareholders 107.2   114.3   140.0  
 
Weighted average diluted common shares outstanding – diluted (two
class) (in millions)
192.5 194.1 196.9
Diluted earnings per share (two class) (in US$) 0.48 0.54 0.82
Adjusted diluted earnings per share (two class) (in US$) 0.56 0.59 0.71
1   Distribution expenses are paid to financial intermediaries for the
distribution of JHG’s investment products. JHG management believes
that the deduction of third-party distribution, service and advisory
expenses from revenue in the computation of net revenue reflects the
nature of these expenses, as these costs are passed through to
external parties that perform functions on behalf of, and
distribute, the Group’s managed AUM.
2 Adjustments primarily represent integration costs in relation to the
Merger, including severance costs, legal costs and consulting fees.
JHG management believes these costs do not represent the ongoing
operations of the Group.
3 Investment management contracts have been identified as a separately
identifiable intangible asset arising on the acquisition of
subsidiaries and businesses. Such contracts are recognised at the
net present value of the expected future cash flows arising from the
contracts at the date of acquisition. For segregated mandate
contracts, the intangible asset is amortised on a straight-line
basis over the expected life of the contracts. JHG management
believes these non-cash and acquisition-related costs do not
represent the ongoing operations of the Group.
4 Adjustments for the three months ended 31 March 2019 and 31 December
2018 primarily represent increased debt expense as a consequence of
the fair value uplift on debt due to acquisition accounting and
deferred consideration costs associated with acquisitions prior to
the Merger. Adjustments for the three months ended 31 March 2018
include the gain on the sale of JHG’s back-office, middle-office and
custody function in the US to BNP Paribas, fair value movement on
options issued to Dai-ichi in addition to the same adjustments
affecting the three-month 2019 period. JHG management believes these
costs do not represent the ongoing operations of the Group.
5 The tax impact of the adjustments is calculated based on the US or
foreign statutory tax rate as they relate to each adjustment.
Certain adjustments are either not taxable or not tax-deductible.
 
           

Condensed consolidated balance sheets (unaudited)

 
31 Mar 31 Dec
(in US$ millions) 2019 2018
Assets
Cash and cash equivalents 717.1 880.4
Investment securities 270.7 291.8
Property, equipment and software, net 72.6 69.5
Intangible assets and goodwill, net 4,619.0 4,601.3
Assets of consolidated variable interest entities 330.0 323.9
Other assets 1,013.7 745.0
Total assets 7,023.1 6,911.9
 
Liabilities, redeemable noncontrolling interests and equity
Debt 318.4 319.1
Deferred tax liabilities, net 730.7 729.9
Liabilities of consolidated variable interest entities 11.0 6.5
Other liabilities 950.9 859.5
Redeemable noncontrolling interests 137.0 136.1
Total equity 4,875.1 4,860.8
Total liabilities, redeemable noncontrolling interests and equity 7,023.1 6,911.9
 
     

Condensed consolidated statements of cash flows (unaudited)

 
Three months ended
(in US$ millions) 31 Mar

2019

      31 Dec

2018

      31 Mar

2018

Cash provided by (used for)
Operating activities (34.7 ) 243.3 61.7
Investing activities 51.3 13.0 11.6
Financing activities (198.3 ) (127.8 ) (208.2 )
Effect of foreign exchange rate changes 5.0   (8.0 ) 6.1  
Net change during period (176.7 ) 120.5   (128.8 )
 

STATUTORY DISCLOSURES

Associates and joint ventures

At 31 March 2019, the Group holds interests in the following associates
and joint ventures managed through shareholder agreements with third
party investors, accounted for under the equity method:

  • Long Tail Alpha LLC. Ownership 20%

Basis of preparation

In the opinion of management of Janus Henderson Group plc, the condensed
consolidated financial statements contain all normal recurring
adjustments necessary to fairly present the financial position, results
of operations and cash flows of JHG in accordance with US GAAP. Such
financial statements have been prepared in accordance with the
instructions to Form 10-Q pursuant to the rules and regulations of the
SEC. Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been
condensed or omitted pursuant to such rules and regulations. The
financial statements should be read in conjunction with the annual
consolidated financial statements and notes presented in Janus Henderson
Group’s Annual Report on Form 10-K for the year ended 31 December 2018,
on file with the SEC (Commission file no. 001-38103). Events subsequent
to the balance sheet date have been evaluated for inclusion in the
financial statements through the issuance date and are included in the
notes to the condensed consolidated financial statements.

Corporate governance principles and recommendations

In the opinion of the Directors, the financial records of the Group have
been properly maintained, and the Condensed Consolidated Financial
Statements comply with the appropriate accounting standards and give a
true and fair view of the financial position and performance of the
Group. This opinion has been formed on the basis of a sound system of
risk management and internal control which is operating effectively.

FORWARD-LOOKING STATEMENTS DISCLAIMER

Past performance is no guarantee of future results. Investing involves
risk, including the possible loss of principal and fluctuation of value.

This document includes statements concerning potential future events
involving Janus Henderson Group plc that could differ materially from
the events that actually occur. The differences could be caused by a
number of factors including those factors identified in Janus Henderson
Group’s Annual Report on Form 10-K for the fiscal year ended 31 December
2018, on file with the Securities and Exchange Commission (Commission
file no. 001-38103), including those that appear under headings such as
‘Risk Factors’ and ‘Management’s Discussion and Analysis of Financial
Condition and Results of Operations’. Many of these factors are beyond
the control of JHG and its management. Any forward-looking statements
contained in this document are as at the date on which such statements
were made. Janus Henderson Group assumes no duty to update them, even if
experience, unexpected events, or future changes make it clear that any
projected results expressed or implied therein will not be realised.

Annualised, pro forma, projected and estimated numbers are used for
illustrative purposes only, are not forecasts and may not reflect actual
results.

The information, statements and opinions contained in this document do
not constitute a public offer under any applicable legislation or an
offer to sell or solicitation of any offer to buy any securities or
financial instruments or any advice or recommendation with respect to
such securities or other financial instruments.

Not all products or services are available in all jurisdictions.

Mutual funds in the US are distributed by Janus Henderson Distributors.

Please consider the charges, risks, expenses and investment
objectives carefully before investing. For a US fund prospectus or, if
available, a summary prospectus containing this and other information,
please contact your investment professional or call 800.668.0434. Read
it carefully before you invest or send money.

Janus Henderson, Janus, Henderson, Intech, Alphagen and Knowledge.
Shared are trademarks of Janus Henderson Group plc or one of its
subsidiaries. © Janus Henderson Group plc.

Contacts

Investor enquiries:
John Groneman
Global Head of
Investor Relations
+44 (0) 20 7818 2106
[email protected]

Jim
Kurtz
US Investor Relations Manager
+1 (303) 336 4529
[email protected]

Melanie
Horton
Non-US Investor Relations Manager
+44 (0) 20 7818 2905
[email protected]

Or

Investor
Relations
[email protected]

Media
enquiries:

North America:
Taylor Smith
+1 303
336 5031
[email protected]

EMEA:
Sally
Todd
+44 (0) 20 7818 2244
[email protected]

United
Kingdom: FTI Consulting

Tom Blackwell
+ 44 (0) 20 3727 1051
[email protected]

Asia
Pacific: Honner

Michael Mullane
+ 61 28248 3740
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading

Cannabis

Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania